Your best medicine news resource
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
NICE (National Institute for Health and Clinical Excellence) has announced, in its Final Appraisal Determination (FAD), that Baraclude(R) (entecavir) is recommended as an option for treatment of eligible patients with chronic hepatitis B (CHB).
More: continued here
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
Roche announced that the European Commission has approved a shortened, 16-week course of treatment with Pegasys (peginterferon alfa-2a (40 KD)) plus Copegus (ribavirin) for certain hepatitis C patients.
More: continued here
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A. announced that all 553 enrolled patients successfully completed a Phase 3 trial. After 48 weeks of therapy, all patients responding to treatment have now completed their 24-week follow-up. The unblinded data from the trial are expected to be available in the fourth quarter of 2008.
More: continued here
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
A new large, prospective population-based study confirms an inverse relationship between coffee consumption and liver cancer risk. The study also found that higher levels of gamma-glutamyltransferase (GGT) in the blood were associated with an increased risk of developing the disease. These findings are published in the July issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).
More: continued here
Jun 30th 2008Drug InformationLiver Disease / Hepatitis
Gene-expression data from liver tissue or whole blood can be used to classify histopathologic differences in the effects of hepatotoxins. It is hoped that these findings, published in BioMed Central’s open access journal, Genome Biology, will lead to a more precise way of defining the potential hepatotoxicity of new compounds. It is already known that toxins can be classified using transcriptomic data taken from the primary target tissue or organ.
More: continued here
Jun 10th 2008Drug InformationLiver Disease / Hepatitis
Nearly 9 percent of patients who recently underwent liver transplantation suffered a subsequent surgical site infection (SSI). Risk factors included having had biliary-enteric anastomosis (choledocho-jejunal or hepatic-jejunal reconstruction), previous liver or kidney transplant, and more than four red blood cell units transfused. These findings are published in the June issue of Liver Transplantation, a journal by John Wiley & Sons.
More: continued here
Jun 10th 2008Drug InformationLiver Disease / Hepatitis
A gap in survival rates between whites and minorities who had received a liver transplant appears to have been eliminated, possibly due to the introduction of a new medication to prevent organ rejection, new research finds, Reuters reports. Johnny Hong of the University of California-Los Angeles
More: continued here
Jun 10th 2008Drug InformationLiver Disease / Hepatitis
Immtech Pharmaceuticals, Inc. (Amex: IMM) announced positive results against the hepatitis C virus (HCV) of a compound from its drug discovery portfolio. The prototype compound belongs to an expanding class of compounds that has previously demonstrated activity against a related surrogate virus, bovine viral diarrhea virus (BVDV).
More: continued here
Jun 1st 2008Drug InformationLiver Disease / Hepatitis
With the launch of the Hepatitis C Action Plan for Scotland Phase II, the Scottish Government has promised over £43 million to help tackle the spread of this virus. The plan will help to significantly improve testing, treatment, care and support services for Hepatitis C across Scotland. In addition, in order to increase prevention, national education and awareness initiatives will also be increased.
More: continued here
Jun 1st 2008Drug InformationLiver Disease / Hepatitis
A new study reveals patients with liver cancer who have no other treatment options might benefit from more aggressive operations once considered too risky, report University of Florida scientists, who also published research this month yielding insight into ways to protect the liver during surgery.
More: continued here
Your best medicine news resource
